AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca total assets ($M) ($M)
Form 20-F & Form 6-K Consolidated Statement of Financial Position (Postgres DB)
Latest, Q2 2026
115,833
Period ended Jun 30, 2026
Change on a year earlier
+3.0%
112,422 in Q2 2025
History
21 quarters
Since Q4 2015
Sources
18
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total assets ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 115,833 | +3.0% | Form 6-K (filed 2026-07-27) ↗ |
| Q4 2025 | Dec 31, 2025 | 114,074 | +9.6% | Form 20-F (filed 2026-02-24) ↗ |
| Q2 2025 | Jun 30, 2025 | 112,422 | +7.7% | Form 6-K (filed 2025-07-29) ↗ |
| Q4 2024 | Dec 31, 2024 | 104,035 | +2.9% | Form 20-F (filed 2025-02-18) ↗ |
| Q2 2024 | Jun 30, 2024 | 104,340 | +8.1% | Form 6-K (filed 2024-07-25) ↗ |
| Q4 2023 | Dec 31, 2023 | 101,119 | +4.8% | Form 20-F (filed 2024-02-20) ↗ |
| Q2 2023 | Jun 30, 2023 | 96,543 | 0.0% | Form 6-K (filed 2023-07-28) ↗ |
| Q4 2022 | Dec 31, 2022 | 96,483 | -8.4% | Form 20-F (filed 2023-02-21) ↗ |
| Q2 2022 | Jun 30, 2022 | 96,579 | +31.1% | Form 6-K (filed 2022-07-29) ↗ |
| Q4 2021 | Dec 31, 2021 | 105,363 | +57.9% | Form 20-F (filed 2022-02-22) ↗ |
| Q2 2021 | Jun 30, 2021 | 73,641 | +22.9% | Form 6-K (filed 2021-07-30) ↗ |
| Q4 2020 | Dec 31, 2020 | 66,729 | +8.7% | Form 20-F (filed 2021-02-16) ↗ |
| Q2 2020 | Jun 30, 2020 | 59,929 | -3.2% | Form 6-K/A (filed 2020-07-31) ↗ |
| Q4 2019 | Dec 31, 2019 | 61,377 | +1.2% | Form 20-F (filed 2020-03-03) ↗ |
| Q2 2019 | Jun 30, 2019 | 61,889 | +0.9% | Form 6-K (filed 2019-07-25) ↗ |
| Q4 2018 | Dec 31, 2018 | 60,651 | -4.3% | Form 20-F (filed 2019-03-05) ↗ |
| Q2 2018 | Jun 30, 2018 | 61,344 | -5.8% | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2017 | Dec 31, 2017 | 63,354 | +1.3% | Form 20-F (filed 2018-03-06) ↗ |
| Q2 2017 | Jun 30, 2017 | 65,119 | – | Form 6-K (filed 2018-07-26) ↗ |
| Q4 2016 | Dec 31, 2016 | 62,526 | +4.1% | Form 20-F (filed 2018-03-06) ↗ |
| Q4 2015 | Dec 31, 2015 | 60,056 | – | Form 20-F (filed 2018-03-06) ↗ |
Breakdown
What makes up total assets ($m)
- Total current assets ($M)27,965 · Q2 2026
- Property, plant and equipment ($M)13,615 · Q2 2026
- Right-of-use lease assets ($M)2,685 · Q2 2026
- Goodwill ($M)21,181 · Q2 2026
- Intangible assets ($M)37,723 · Q2 2026
- Deferred tax assets ($M)6,487 · Q2 2026
- Total liabilities ($M)65,463 · Q2 2026
- Total equity ($M)50,370 · Q2 2026
Cite this data
StockData. (2026). AstraZeneca Total assets ($M) ($M), quarterly Q4 2015–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/fin_assets
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.